Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0002-9378(16)35443-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of the Performance of the Dose Calibrator Used in Radioactivity Measurement.
Indian J Nucl Med
November 2024
Center for Research and Production of Radioisotopes, Dalat Nuclear Research Institute, Vietnam Atomic Energy Institute (VINATOM), Da Lat City, Lam Dong Province, Vietnam.
Aims: This study aimed to evaluate the principal technical characteristics of a well-type gas-filled ionization chamber dose calibrator used in measuring radiopharmaceutical activity, namely accuracy, repeatability, and linearity. Furthermore, this work also explored the correlation between the device's response and the position and volume of the radiopharmaceutical I-131.
Materials And Methods: Experimental measurements were conducted on the ATOMLAB 500 dose calibrator using NIST traceable Cs-137 source to determine the accuracy and repeatability.
Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study.
EBioMedicine
January 2025
Department of Human Oncology, UW School of Medicine and Public Health, Madison, WI, USA.
Background: Re-irradiation of recurrent head and neck cancer (HNC) is often limited by tumour adherence to critical structures and/or radiation tolerance of critical normal tissues. Iopofosine I 131 (CLR 131) is a targeted small molecular phospholipid ether (PLE) drug conjugate that delivers iodine-131 selectively to tumour cells. We conducted a phase 1, single-centre, open-label study to determine whether CLR 131 given with reduced dose of external beam radiation therapy (EBRT) would be tolerable and feasible.
View Article and Find Full Text PDFUnexpected Victory: High-Risk Papillary Thyroid Cancer with Distant Metastases Shows Extraordinary Response to First RAI Treatment.
J Pak Med Assoc
December 2024
Department of Nuclear Medicine, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
Papillary Thyroid Cancer (PTC) is the most prevalent type of differentiated thyroid cancer. Its incidence is growing worldwide although it has low death rates. Treatment includes surgery followed by radioactive iodine therapy.
View Article and Find Full Text PDFEnhancing the radionuclide theranostic concept through the radiohybrid approach.
RSC Med Chem
November 2024
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research Bautzner Landstraße 400 D-01328 Dresden Germany
Radionuclide theranostics - a fast-growing emerging field in radiopharmaceutical sciences and nuclear medicine - offers a personalised and precised treatment approach by combining diagnosis with specific and selective targeted endoradiotherapy. This concept is based on the application of the same molecule, labelled with radionuclides possessing complementary imaging and therapeutic properties, respectively. In radionuclide theranostics, radionuclide pairs consisting of the same element, such as Cu/Cu, Pb/Pb or I/I are of significant interest due to their identical chemical and pharmacological characteristics.
View Article and Find Full Text PDFLocalization and Tumor Growth Inhibition of I-131-Labeled Monoclonal Antibody ERIC1 in a Subcutaneous Xenograft Model of Small Cell Lung Cancer in SCID Mice.
Int J Mol Sci
October 2024
Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
This study evaluates the efficacy of [I]I-ERIC1 in targeting and inhibiting the growth of SCLC tumors in mice, focusing on tumor accumulation and regression and potential side effects. NCAM-positive NCI-H69 SCLC cells were implanted in CB 17 SCID mice, and [I]I-ERIC1 biokinetics were measured in organs and tissues at four post-injection time points (24, 72, 96, and 120 h). The experimental series compared tumor growth, survival, and changes in blood counts among three treatment groups (1, 2, or 3 MBq) and a control group, with treatments initiated either two or five days post implantation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!